Oral Absorption of Ginsenoside Rb1usingin vitroandin vivoModels

Authors:
  • XSXianyi Sha
    Xianyi Sha
  • YWYunjuan Wu
    Yunjuan Wu
  • XFXiaoling Fang
    Xiaoling Fang

Abstract
This research attempts to clarify the cause for poor oral absorption of ginsenoside Rb1 (Rb1), one main ingredient of the well known Panax notoginseng saponins (PNS) for curing hemorrhage. Caco-2 cell monolayers were used as an in vitro model to reveal the transport mechanism of Rb1 across the intestinal mucosa. Moreover, the serum concentration-time profiles of Rb1 after tail venous (IV), portal venous (PV), intraduodenal (ID) and peroral (PO) administration to rats were compared to evaluate the first-pass effects of stomach, intestine and liver. In vitro experiments showed that uptake by Caco-2 cell monolayers was temperature dependent, but was not influenced by cyclosporine A and ketoconazole. The change in the apical pH showed no obvious effects on the uptake of Rb1. The uptake and transport were non-saturable, and flux from the apical compartment to the basolateral compartment (A - B) increased linearly with increasing concentration, which indicated a passive transport. Meanwhile, an apparent permeability coefficient of (5.90 ± 1.02) × 10-8 cm/s (C0 = 1 mg/mL) predicted an incomplete absorption. The investigation on the pharmacokinetic behavior of Rb1 after different routes of administration to rats showed a significant difference between PO (FPO was 0.64 %), ID (FID was 2.46 %) and PV (FPV was 59.49 %) administration, and the first-pass effect of the intestine is more significant than that of the stomach and liver in the absorption process. In summary, elimination in the stomach, large intestine and liver contributed to the poor absorption of Rb1, but the low membrane permeability might be a more important factor dominating the extent of absorption. Rb1:ginsenoside Rb1 PNS:Panax notoginseng A:apical B:basolateral HEPES:N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid MES:2-N-morpholineethanesulfonic acid HBSS:Hanks balanced salt solution CsA:cyclosporine A KCZ:ketoconazole Papp:apparent permeability coefficient PO:peroral (administration) ID:intraduodenal (administration) PV:portal venous (administration) IV:tail venous (administration) FPO:absolute bioavailability after peroral administration FID:absolute bioavailability after intraduodenal administration FPV:absolute bioavailability after portal venous administration FIV:absolute bioavailability after tail venous administration